Here’s Why We’re Excited About The Upcoming Minerva Neurosciences Inc (NERV) Data

Page 2 of 2

And here’s the exciting part.

The trial completed during the third quarter (the assumption here is that it was mid to late September, so only just completed) and the company is un-blinding and analyzing the data as we speak. Once the analysis is complete, Minerva will put out topline from the extension, with a target of mid fourth quarter.

Why is this exciting?

Because last time the company put out data supportive of an efficacy bias with MIN-101, the company jumped nearly 250%. If the extension data supports the initial hypothesis – that is, if it suggests the drug is effective beyond the initial trial period – then it will massively increase the potential market for the drug.

That’s why this is important, and that’s what markets seem to be overlooking right now.

Follow Minerva Neurosciences Inc. (NASDAQ:NERV)

Note: This article is written by Mark Collins and was originally published at Market Exclusive.
Correction: an earlier version of this article stated that the number of patients enroled in Minerva Neurosciences’ initial study that advanced in to the extension phase stood at 14 instead of 140.
Page 2 of 2